Prescription RequiredProduct Introduction
Vylda-M 500 Tablet is a medication that combines two active ingredients: Metformin and Vildagliptin. Metformin belongs to the biguanide class of antidiabetic drugs, while Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination is used to manage type 2 diabetes mellitus by controlling blood sugar levels.
Uses of Vylda-M 500 Tablet
Vylda-M 500 Tablet is primarily prescribed to individuals with type 2 diabetes mellitus to help regulate blood glucose levels. Here are the main uses:
- Type 2 Diabetes Mellitus Management: Vylda-M 500 Tablet helps lower blood sugar levels by enhancing insulin sensitivity in the body and reducing glucose production in the liver.
- Adjunct Therapy: It is often used when lifestyle changes such as diet and exercise alone have not been sufficient to control blood sugar levels.
Benefits of Vylda-M 500 Tablet
- Effective Blood Sugar Control: By combining Metformin and Vildagliptin, Vylda-M 500 Tablet offers dual-action benefits that help maintain stable blood glucose levels throughout the day.
- Improved Insulin Sensitivity: Metformin enhances the body’s response to insulin, making it more effective in transporting glucose into cells for energy production.
- Reduction in HbA1c Levels: Long-term use of Vylda-M 500 Tablet has been shown to reduce glycosylated hemoglobin (HbA1c) levels, indicating better overall blood sugar control over time.
- Weight Neutral: Unlike some other diabetes medications, Vylda-M 500 Tablet is weight neutral, meaning it does not typically cause significant weight gain.
Side Effects of Vylda-M 500 Tablet
Like all medications, Vylda-M 500 Tablet may cause side effects, although not everyone experiences them. Common side effects include:
- Gastrointestinal Upset: This may include nausea, vomiting, diarrhea, or stomach discomfort. Taking the medication with food can often help reduce these symptoms.
- Hypoglycemia: Low blood sugar levels can occur, especially if the medication is not taken regularly or if there are changes in diet or physical activity levels.
- Headache: Some individuals may experience mild to moderate headaches, which usually resolve with continued use.
- Dizziness or Weakness: These symptoms can occur, particularly when starting the medication or if the dose is too high.
References
-
Vildagliptin/metformin hydrochloride. Nuremberg, Germany: Novartis Pharma GmbH; 2018. [Accessed 22 Jan. 2019] (online) Available from:
-
Vildagliptin/metformin hydrochloride. Macquarie Park, New South Wales: Novartis Pharmaceuticals Australia Pty Limited; 2010 [revised 8 Nov. 2018]. [Accessed 22 Jan. 2019] (online) Available from:
-
Vildagliptin. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd.; 2007 [26 Apr. 2018] [Accessed 08 Apr. 2019] (online) Available from:
-
Metformin hydrochloride. Princeton, New Jersey: Bristol-Myers Squibb Company. [Accessed 08 Apr. 2019] (online) Available from:
-
Vildagliptin/Metformin (Vilact-M) [Product Monograph]. Mumbai, Maharashtra: Panacea Biotec Limited; 2019. [Accessed 20 Oct. 2021] (online) Available from:
-
Vildagliptin/Metformin hydrochloride [EMC Label]. Nuremberg, Germany: Novartis Pharma GmbH; 2021. [Accessed 20 Oct. 2021] (online) Available from:
Disclaimer
Singhla Medicos primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.
Cold chain
Reviews
There are no reviews yet.